Ovarian cancer laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Hudakarman (talk | contribs) No edit summary |
Hudakarman (talk | contribs) Laboratory findings |
||
Line 7: | Line 7: | ||
* Patients with ovarian cancer can present acutely or sub-acutely | * Patients with ovarian cancer can present acutely or sub-acutely | ||
* If there is clinical suspicion of malignancy, the evaluation include laboratory work, imaging and surgical exploration for the definite diagnosis | * If there is clinical suspicion of malignancy, the evaluation include laboratory work, imaging and surgical exploration for the definite diagnosis | ||
*CBC | |||
*CBP | |||
*Serum biomarkers: | |||
** CA 125 | |||
*** Postmenopausal woman: should be measured | |||
*** Premenopausal woman: should be measured only if US shows highly suspicious malignant mass | |||
* | * | ||
Revision as of 16:10, 10 July 2019
Ovarian cancer Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Ovarian cancer laboratory findings On the Web |
American Roentgen Ray Society Images of Ovarian cancer laboratory findings |
Risk calculators and risk factors for Ovarian cancer laboratory findings |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
- Patients with ovarian cancer can present acutely or sub-acutely
- If there is clinical suspicion of malignancy, the evaluation include laboratory work, imaging and surgical exploration for the definite diagnosis
- CBC
- CBP
- Serum biomarkers:
- CA 125
- Postmenopausal woman: should be measured
- Premenopausal woman: should be measured only if US shows highly suspicious malignant mass
- CA 125